Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S. -- Update
By Thomas M. Burton
Federal health regulators have decided to allow the resumption
of U.S. studies of a leading Covid-19 vaccine candidate from
AstraZeneca PLC and the University of Oxford, according to a person
familiar with the matter and materials reviewed by The Wall Street
The U.S. Food and Drug Administration has wrapped up its
examination of two cases of a possible neurological side effect
that emerged in two people testing the shot. The agency told
AstraZeneca on Friday that the late-stage trial in the U.S. can
resume, according to the person and materials.
The FDA didn't find the vaccine was responsible for the two
cases, though it couldn't rule out a link either, the person
The agency plans to require researchers to inform study subjects
of the cases and monitor them for any related neurological events,
such as numbness, the person said.
AstraZeneca declined to comment.
The vaccine is among the most advanced in development. If it
proves to work safely, it could be one of the first, if not the
first, greenlighted by regulators for widespread use.
The vaccine had been on track to be authorized for widespread
use before year's end, if it proved to work safely in the
Last month, however, AstraZeneca paused trials testing the shot
around the world, including in the U.S., after a U.K. woman
developed a mysterious neurological illness. A U.S. health official
had said the event involved a spinal cord problem.
The illness followed a pause in testing, in July, after an
unexplained illness of a trial subject. Researchers initially told
subjects in the study the case involved a neurological disorder
known as transverse myelitis. AstraZeneca later said the case
turned out to be multiple sclerosis unrelated to the vaccine, and
the testing resumed.
Studies testing the vaccine around the world later resumed after
regulators outside the U.S. determined it was safe to do so, except
a late-stage trial in the U.S. because the FDA was still
investigating the two events.
The FDA has spent weeks exploring whether the two cases involved
transverse myelitis and whether the vaccine was responsible for the
illness, the person said.
An AstraZeneca spokesman has said the company was working with
the FDA so it can evaluate whether the U.S. trial can resume. All
the studies testing the shots are being closely watched for safety,
including by health regulators in various countries, the spokesman
Reuters had earlier reported the U.S. trial could resume this
Transverse myelitis is a known side effect of vaccines but is
rarely linked to the shots. Other times, it is an early symptom of
the nerve-system disease multiple sclerosis, and unrelated to
getting a shot.
The condition refers to inflammation of the spinal cord
involving the destruction of a fatty white material, known as
myelin, that insulates nerve cell fibers. It impedes the ability of
nerves in the spinal cord to send messages to the rest of the
Cases are rare, with only about 1,400 diagnosed annually in the
U.S. The cause is unknown. It can trigger a variety of symptoms,
including weak arms and legs, along with sharp pains, numbness and
It can sometimes also lead to paraplegia that necessitates
Experimental vaccines undergo study, in trials that
progressively test the shots in increasing numbers of volunteers,
both to test effectiveness and to look for any side effects that
could harm people if regulators greenlighted the vaccines and they
were then given widely.
To protect trial subjects, independent researchers who didn't
play a role in the vaccine's development, or at the company that
would sell it, look for any signs that the shot could be harmful.
This data-safety monitoring board evaluates side effects in
Side effects often emerge in trials evaluating drugs and
vaccines, and the studies are frequently paused for researchers and
regulators to make sure it is safe to go on.
Since the trial for the vaccine from AstraZeneca and Oxford was
put on hold, studies of Johnson & Johnson's Covid-19 vaccine
candidate and of a combination of Eli Lilly & Co.'s antibody
and Gilead Sciences Inc.'s antiviral remdesivir w ere paused.
AstraZeneca was among the drugmakers that pledged to not seek
regulators' permission for widespread use of their Covid-19
vaccines until the shots proved to work safely in late-stage
--Joseph Walker contributed to this article.
Write to Thomas M. Burton at email@example.com
(END) Dow Jones Newswires
October 23, 2020 14:41 ET (18:41 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Historical Stock Chart
From Nov 2020 to Dec 2020
Historical Stock Chart
From Dec 2019 to Dec 2020